Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wunderink

Showing results (371-380 of 545) with videos related to

Pageof 55
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigmLala M Dunbar, Richard G Wunderink, Michael P Habib, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2021
Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired PneumoniaNathaniel J Rhodes, Caroline C Jozefczyk, W Justin Moore, et al.
Journal of the American Geriatrics Society|September 14, 2001
Airflow limitation is underrecognized in well-functioning older peopleG W Waterer, J Y Wan, S B Kritchevsky, et al.
Critical Care Medicine|March 11, 2003
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failureEdward Abraham, Chris Naum, Venkata Bandi, et al.
International Journal of Medical Sciences|December 4, 2024
Clinical and Epidemiologic Features of <i>Mycoplasma pneumoniae</i> Infection Among Adults Hospitalized with Community-acquired PneumoniaPreeta K Kutty, Seema Jain, Maureen H Diaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 3, 2016
Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project TeamHelen Donnelly, Demissie Alemayehu, Radu Botgros, et al.
Open Forum Infectious Diseases|July 31, 2023
An Adjudication Protocol for Severe PneumoniaChiagozie I Pickens, Catherine A Gao, Justin Bodner, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 5, 2021
Torque teno virus loads after kidney transplantation predict allograft rejection but not viral infectionAline L van Rijn, Herman F Wunderink, Igor A Sidorov, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1994
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study GroupM P Fink, D R Snydman, M S Niederman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 29, 2018
Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for TestingShawna Bellew, Carlos G Grijalva, Derek J Williams, et al.
Pageof 55

Showing results (371-380 of 545) with videos related to

Sort By:
Pageof 55
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigmLala M Dunbar, Richard G Wunderink, Michael P Habib, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2021
Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired PneumoniaNathaniel J Rhodes, Caroline C Jozefczyk, W Justin Moore, et al.
Journal of the American Geriatrics Society|September 14, 2001
Airflow limitation is underrecognized in well-functioning older peopleG W Waterer, J Y Wan, S B Kritchevsky, et al.
Critical Care Medicine|March 11, 2003
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failureEdward Abraham, Chris Naum, Venkata Bandi, et al.
International Journal of Medical Sciences|December 4, 2024
Clinical and Epidemiologic Features of <i>Mycoplasma pneumoniae</i> Infection Among Adults Hospitalized with Community-acquired PneumoniaPreeta K Kutty, Seema Jain, Maureen H Diaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 3, 2016
Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project TeamHelen Donnelly, Demissie Alemayehu, Radu Botgros, et al.
Open Forum Infectious Diseases|July 31, 2023
An Adjudication Protocol for Severe PneumoniaChiagozie I Pickens, Catherine A Gao, Justin Bodner, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 5, 2021
Torque teno virus loads after kidney transplantation predict allograft rejection but not viral infectionAline L van Rijn, Herman F Wunderink, Igor A Sidorov, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1994
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study GroupM P Fink, D R Snydman, M S Niederman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 29, 2018
Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for TestingShawna Bellew, Carlos G Grijalva, Derek J Williams, et al.
Pageof 55